Estimating vaccine costs for epi cost-effectiveness analysis
β Scribed by Rachel Feilden
- Publisher
- John Wiley and Sons
- Year
- 1990
- Tongue
- English
- Weight
- 298 KB
- Volume
- 5
- Category
- Article
- ISSN
- 0749-6753
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Our objective in this study was to determine the costeffectiveness of hepatitis A vaccination strategies in healthy adults in the United States. We constructed a decision model simulating costs and health consequences for otherwise healthy adults with respect to hepatitis A prevention. Three strateg
## Abstract The G8 is considering committing to purchase vaccines against diseases concentrated in lowβincome countries (if and when desirable vaccines are developed) as a way to spur research and development on vaccines for these diseases. Under such an βadvance market commitment,β one or more spo
A model creates the framework for a cost-e!ectiveness analysis, allowing decision makers to explore the implications of using an intervention in di!erent ways and under di!erent conditions. To serve its purpose a model must produce accurate predictions and allow for substantial variation in the fact